LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

Search

Omnicell Inc

Open

BrancheGesundheitswesen

46.81 0.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

45.74

Max

47.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

-177K

5.5M

Verkäufe

20M

311M

KGV

Branchendurchschnitt

100.628

76.798

EPS

0.51

Gewinnspanne

1.758

Angestellte

3,600

EBITDA

524K

31M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+1.18% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

585M

2B

Vorheriger Eröffnungskurs

46.01

Vorheriger Schlusskurs

46.81

Nachrichtenstimmung

By Acuity

50%

50%

167 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Omnicell Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Dez. 2025, 23:54 UTC

Heiße Aktien

Stocks to Watch: Nike, Cassava Sciences, KB Home

18. Dez. 2025, 23:51 UTC

Ergebnisse

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18. Dez. 2025, 23:39 UTC

Wichtige Markttreiber

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18. Dez. 2025, 21:40 UTC

Ergebnisse

Nike Sales Tick Up, But China Weakness Persists

18. Dez. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18. Dez. 2025, 23:37 UTC

Market Talk
Ergebnisse

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18. Dez. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18. Dez. 2025, 23:03 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18. Dez. 2025, 23:02 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18. Dez. 2025, 23:00 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18. Dez. 2025, 22:58 UTC

Akquisitionen, Fusionen, Übernahmen

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18. Dez. 2025, 22:57 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18. Dez. 2025, 22:56 UTC

Akquisitionen, Fusionen, Übernahmen

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18. Dez. 2025, 22:55 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:59 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:50 UTC

Market Talk
Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

18. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18. Dez. 2025, 21:35 UTC

Ergebnisse

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18. Dez. 2025, 21:31 UTC

Ergebnisse

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev Down 17% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q EPS 53c >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Apparel Rev $3.91B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Equipment Rev $550M >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q N Amer Rev $5.63B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Footwear Rev $7.66B >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18. Dez. 2025, 21:15 UTC

Ergebnisse

Nike 2Q Greater China Rev $1.42B >NKE

Peer-Vergleich

Kursveränderung

Omnicell Inc Prognose

Kursziel

By TipRanks

1.18% Vorteil

12-Monats-Prognose

Durchschnitt 46.33 USD  1.18%

Hoch 50 USD

Tief 43 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Omnicell Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

24.23 / 30.44Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

167 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Omnicell Inc

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
help-icon Live chat